Shares of Enveric Biosciences, Inc. (NASDAQ:ENVB – Get Free Report) rose 5.9% during mid-day trading on Friday . The stock traded as high as $1.02 and last traded at $0.98. Approximately 203,914 shares traded hands during trading, a decline of 94% from the average daily volume of 3,225,290 shares. The stock had previously closed at $0.93.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Enveric Biosciences in a report on Tuesday, January 30th.
Get Our Latest Research Report on Enveric Biosciences
Enveric Biosciences Stock Up 5.9 %
Enveric Biosciences (NASDAQ:ENVB – Get Free Report) last issued its quarterly earnings data on Monday, March 25th. The company reported ($1.46) EPS for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.09. Equities research analysts anticipate that Enveric Biosciences, Inc. will post -1.98 EPS for the current fiscal year.
Institutional Trading of Enveric Biosciences
An institutional investor recently raised its position in Enveric Biosciences stock. AdvisorShares Investments LLC boosted its position in Enveric Biosciences, Inc. (NASDAQ:ENVB – Free Report) by 46.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 146,833 shares of the company’s stock after buying an additional 46,404 shares during the quarter. AdvisorShares Investments LLC owned approximately 6.73% of Enveric Biosciences worth $339,000 at the end of the most recent quarter. 13.82% of the stock is currently owned by hedge funds and other institutional investors.
Enveric Biosciences Company Profile
Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.
Featured Stories
- Five stocks we like better than Enveric Biosciences
- What does consumer price index measure?
- Appleās Earnings Show Investors Its Strength and Its Weakness
- Learn Technical Analysis Skills to Master the Stock Market
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- Canada Bond Market Holiday: How to Invest and Trade
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.